Guidance, NICE advice and quality standards in development | Guidance

Showing 251 to 260 of 435

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]	Technology appraisal guidance	TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]	Technology appraisal guidance	14 January 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC